All posts by medical

Neuroscience Antibodies & Assays Market Increasing Demand with Leading Player, Comprehensive Analysis and Forecast 2026 – https://sciencein.me/

New Jersey, United States:The Neuroscience Antibodies & Assays Market is analyzed in depth in the report, with the primary aim of providing accurate market data and useful recommendations so that players can achieve strong growth in the future. The report is compiled by experts and experienced market analysts, which makes it very authentic and reliable. Readers have a thorough analysis of historical and future market scenarios to get a good understanding of market competition and other important issues. The report provides comprehensive information on market dynamics, key segments, key players and various regional markets. It is a complete set of in-depth analysis and research on the Neuroscience Antibodies & Assays market.

The authors of the report highlighted lucrative business prospects, eye-catching trends, regulatory situations and Neuroscience Antibodies & Assays market price scenarios. It is important to note that the report includes a detailed analysis of the macroeconomic and microeconomic factors affecting the growth of the Neuroscience Antibodies & Assays market. It is divided into several sections and chapters so that you can easily understand every aspect of the Neuroscience Antibodies & Assays market. Market participants can use the report to take a look at the future of the Neuroscience Antibodies & Assays market and make significant changes to their operating style and marketing tactics in order to achieve sustainable growth.

Neuroscience Antibodies & Assays Market was valued at USD 2.42 Billion in 2018 and is projected to reach USD 5.14 Billion by 2026, growing at a CAGR of 9.7% from 2019 to 2026.

Get | Download Sample Copy @ https://www.verifiedmarketresearch.com/download-sample/?rid=28342&utm_source=SIM&utm_medium=001

Key Players Mentioned in the Neuroscience Antibodies & Assays Market Research Report:

The competitive landscape of the Neuroscience Antibodies & Assays market is examined in detail in the report, with a focus on the latest developments, the future plans of the main players and the most important growth strategies that they have adopted. The analysts who have written the report have drawn a picture of almost all the main players in the Neuroscience Antibodies & Assays market and highlighted their crucial commercial aspects such as production, areas of activity and product portfolio. All companies analyzed in the report are examined on the basis of important factors such as market share, market growth, company size, production volume, turnover and profit.

Neuroscience Antibodies & Assays Market: Segmentation

The report provides an excellent overview of the key Neuroscience Antibodies & Assays market segments, focusing on their CAGR, market size, market share and potential for future growth. The Neuroscience Antibodies & Assays market is mainly divided by product type, application and region. Each segment in these categories is the subject of in-depth research to familiarize yourself with its growth prospects and key trends. The segment analysis is very important to identify the most important growth pockets of a global market. The report provides specific information on market growth and demand for various products and applications so that players can focus on profitable sectors of the Neuroscience Antibodies & Assays market.

Ask For Discount (Special Offer: Get 25% discount on this report) @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=28342&utm_source=SIM&utm_medium=001

Table of Content

1 Introduction of Neuroscience Antibodies & Assays Market1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Neuroscience Antibodies & Assays Market Outlook4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Neuroscience Antibodies & Assays Market, By Deployment Model5.1 Overview

6 Neuroscience Antibodies & Assays Market, By Solution6.1 Overview

7 Neuroscience Antibodies & Assays Market, By Vertical7.1 Overview

8 Neuroscience Antibodies & Assays Market, By Geography8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Neuroscience Antibodies & Assays Market Competitive Landscape9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix11.1 Related Research

Complete Report is Available @https://www.verifiedmarketresearch.com/product/Neuroscience-Antibodies-&-Assays-Market/?utm_source=SIM&utm_medium=001

We also offer customization on reports based on specific client requirement:

1-Freecountry level analysis forany 5 countriesof your choice.

2-FreeCompetitive analysis of any market players.

3-Free 40 analyst hoursto cover any other data points

About us:

Verified market research partners with the customer and offer an insight into strategic and growth analyzes, Data necessary to achieve corporate goals and objectives. Our core values are trust, integrity and authenticity for our customers.

Analysts with a high level of expertise in data collection and governance use industrial techniques to collect and analyze data in all phases. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research reports.

Contact us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email: [emailprotected]

Get Our Trending Report

https://www.marketresearchblogs.com/

https://www.marktforschungsblogs.com/

Tags: Neuroscience Antibodies & Assays Market Size, Neuroscience Antibodies & Assays Market Trends, Neuroscience Antibodies & Assays Market Forecast, Neuroscience Antibodies & Assays Market Growth, Neuroscience Antibodies & Assays Market Analysis

View post:
Neuroscience Antibodies & Assays Market Increasing Demand with Leading Player, Comprehensive Analysis and Forecast 2026 - https://sciencein.me/

In a Time of Pandemic, What Do People Want to Watch? – Broadcasting & Cable

"To find out, we captured viewers neurologic immersion a second-by-second measurement of what is most valued by the brain while people watched some of the most popular shows on TV and streaming services." -Paul J. Zak, founder, Immersion Neuroscience

Quarantines. Shelter at home. Sickness. Death. These themes have taken over our lives in the era of COVID-19, from conversations with friends to the news we watch and the information we share online. Its a lot like passing a car wreck as hard as we may try, we just cant look away.

In fact, most of us are glued to the news. In the past two weeks local news viewership has increased 11%, and cable news viewership has skyrocketed 73% from the same time last year. Of course, it should be expected that video consumption will go up as more people are confined to their homes. The new norm of self-isolation can be boring, lonesome and depressing, and theres no better way to pass the time than binge watching our favorite shows. But besides the news, what else are people watching? Is all this doom and gloom really what our brains value the most?

Our company recently put this to the test, utilizing the latest advancements in neuroscience technology to assess what people's brains value in the age of the pandemic. Is it more COVID info? TV dramas? Comedies?

To find out, we captured viewers neurologic immersion a second-by-second measurement of what is most valued by the brain while people watched some of the most popular shows on TV and streaming services. Why neurologic immersion? By measuring people's brains using a small sensor worn on the arm rather than asking them what they believe they like we get a far more accurate response. All of our testing was completed remotely while dozens of participants relaxed in the comfort and safety their homes and captured in the cloud.

The programming we assessed ranged from singing competitions to popular comedies and dramas, as well as a network news story about COVID deaths for comparison.

To no surprise, news about COVID-19 generated high immersion in participants. We all want to stay up to date with the latest developments, right? But when participants watched the staff of Dunder Mifflin in the hit-TV sitcom, The Office, neurologic immersion was an astonishing 36% higher producing by far the highest immersion response in our study. For comparison, The Masked Singer, Foxs popular reality singing competition, was only marginally more immersive than the news, at 2% higher.

The other shows we tested were valued significantly lower by participants' brains, despite their popularity among critics and audiences. These included the Netflix cooking show Salt, Fat, Acid Heat (-21%), Amazon Primes drama Too Old to Die Young (-26%) and the Netflix documentary about opioid addiction The Pharmacist (-31%).

So, while news viewership is up, it's not actually what our brains are craving, despite what a viewer might tell you. The brain doesnt lie, and what viewers brains want right now is something funny, familiar and easy to digest.

If youre in the content business, consider giving the people what they really want in this time of pandemic. No, not a vaccine. What we need is the next Friends, Seinfeld or The Office. It might just be the key to saving our sanity until this crisis passes.

Immersion Neuroscience is an advanced predictive software company unlocking neuroscience to measure what people love.

View post:
In a Time of Pandemic, What Do People Want to Watch? - Broadcasting & Cable

A lifetime of fitness helps women’s muscles in old age – Health24

Women who exercise throughout life may keep their muscle power as they age, a new study suggests.

For the study, researchers from Ball State University in Muncie, Indiana, examined muscle strength, power and the size and type of muscle fibres in the thighs of three groups of women.

Seven women in one group were over 70 and had exercised regularly for nearly 50 years. The second group had 10 women who averaged 25 years of age and also worked out regularly. The third group comprised 10 women over 70 who did not exercise regularly.

The over-70 exercisers had more of the "slow-twitch" muscle fibres, the kind of fibres that add to endurance and efficient energy use than women who didn't exercise and young women who did, the researchers found.

Compared with younger exercisers, both groups of older women had smaller fast-twitch fibers, the study showed. That type of muscle contributes more to power than endurance.

Typically, its functioning declines with age.

The older exercisers preserved more fast-twitch power than women who didn't exercise. They also had more power in slow-twitch muscle fibres, researchers added.

The report was published in the Journal of Applied Physiology.

Scott Trappe, professor and director of BSU's Human Performance Laboratory, was one of the leaders of the study.

His team said the findings "are unique and provide new insights into aging skeletal plasticity in women on the myocellular level," according to a journal news release.

Image credit: iStock

Read the rest here:
A lifetime of fitness helps women's muscles in old age - Health24

Organs-on-chips Market Competitive Analysis and Forecast 2017-2025 – Curious Desk

Global AC Organs-on-chips Market: Snapshot

Organs-on-chips or organ-on-a-chip is an electronic gadget that consists of a 3D microfluidic cell culture-based multi-channel structure. This gadget essentially is a chip that can control mechanisms, activities, and physiological responses of organs and organ systems, after being implanted in the body. In a more simplistic manner, this chip acts mainly as an artificial organ, or an artificial system that undertakes processes controlled by human bodies in a natural state. A brisk rise in research in the field of biomedical engineering, particularly to find alternatives for replacing failed human organs has formed a distinct organs-on-chips market.

This market is being pushed to attain substantial growth owing to a rise in healthcare industry applications. Surging cases of organ failure in the form of liver, kidneys, lungs, and heart also are prime reasons for fueling the search to find viable alternatives.

Know the Growth Opportunities in Emerging Markets

The bioelectronics components are mainly created on small microchips, which have tiny chambers formed by living cells. These cells are arranged in such a manner that they mimic human body physiology on a micro-level scale. These simulations are utilized on a macro scale by enhancing them with the help of various methods. According to the organs mentioned above, there are separate chips made for each organ, and even for some smaller constituents that make up an organ. For example, heart-on-a-chip, skin-on-a-chip, artery-on-a-chip, lung-on-a-chip, and kidney-on-a-chip are key organ-on-a-chip gadgets that are being extensively used. Installation of each of these chips depends on several factors such as body acceptability, medical condition of patient, and physiological responses, among others.

Organs-on-chips Market: Overview

Organ-on-chip is multichannel 3D micro-fluidic cell culture gadget, which prompts mechanisms, activities, and physiological reflexes of human organs. This chip builds up a thin channel for the air and blood flow in organs including gut, lung, heart, liver, and so on. This gadgets is created on a microchip, which has constantly perfused chambers made by living cells arranged in a way to invigorate tissue- level physiology and organ-level physiology. It is utilized to sustain interior organs with the support of silicone.

The worldwide organ-on-chip market is fragmented based on geography and type. On the basis of type, the market is partitioned into human-on-chip, heart-on-chip, lungs-on-chip, intestine on-chip, liver-on-chip, and kidney-on-chip. Based on geography the organs-on-chips market is segmented into Europe, North America, Asia-Pacific, Latin America, and the Middle East and Africa.

The analysts of the report have utilized skilled procedures to anticipate the patterns in the market for organs-on-chips keeping in mind the end goal to make precise projections. The examination of different market components has been utilized to illustrate noteworthy, current, and provisional future patterns, which would enable the market players to get a domain of the market.

Organs-on-chips Market:Trends and Prospects

The development of the global organ-on-chip market is driven by rise in its applications in the healthcare industry, increase in demand for drug screening, and soaring demand for kidney applications and lung-based organ culture. Be that as it may, high cost and early stage in research and development obstruct the market development. These components are expected to either drive or hamper the market. But, nevertheless, rise in research processes on organ-on-chips is estimated to offer plenty of opportunities for the leading players.

Deficiency of donor lungs for transplantation has prompted increase in number of patients dying due to illness. In this way, increase in demand to create lab-engineered, functional organs is expected to supplement the development of the market. Recellularized strong organs can perform organ-specific tasks for limited amount of time, which shows the potential for clinical utilization of artificially designed strong organs later on.

Rise in demand for organ-on-chip gadgets in the medical industry is foreseen to help the development of the global market. Organ-on-chip gadgets are known to be useful in in-vitro analysis of biochemical, real-time imaging, and metabolic and genetic activities of living cells in a functional tissue, which majorly boost their adoption.

Drug screening is a practical technique utilized for quickly reviewing samples. Researchers and analysts utilize organ-on-chips culture gadgets to monitor the impacts of medications in the body. Moreover, drug effectiveness or drug toxicity in different organs of the body is checked utilizing this procedure, which helps the market development.

Order this Report TOC for Detailed Statistics

Organs-on-chips Market:Regional Outlook

The heart-on-chip segment has higher potential for development in the global market. Lung-on-chip led the global organ-on-chip market in 2016, and is anticipated to continue its predominance within the forecast period. North America held the biggest market share, because of advanced technological innovations and rise in healthcare applications. Asia-Pacific is expected to witness the most astounding development due to various growth opportunities offered by nations, for example, India, China, and Japan. The accessibility of new and advanced organs-on-chips in the market, and ideal government activities as far as financing and projects for essential drug advancement and research, and the advent of key pharmaceutical organizations. These are regions where the lions share of drug development activity is focused.

Organs-on-chips Market:Vendor Landscape

Emulate, Inc., CN Bio Innovations, Ascendance Biotechnology, Inc., Mimetas B.V., Organovo Holdings, Inc., Tara Biosystems, AxoSim Technologies LLC, Hurel Corporation, Insphero AG, and Nortis Inc. are among the major players in the global organs-on-chips market.

See the article here:
Organs-on-chips Market Competitive Analysis and Forecast 2017-2025 - Curious Desk

Equal roles for women in Indian Armed Forces: The road ahead – WION

The recent decisions of the Supreme Court regarding grant of permanent commission to women officersareseen as a landmark step towards women empowerment and corrective change to prevent perceived gender bias against women.

The concerns expressed by the government, on behalf of Indian Armed Forces, like physiology, motherhood and physical attributes, did not hold ground under the basic tenet of constitutional entitlement to dignity, which attaches to every individual irrespective of gender.

These are welcomed societal changes and the military system has to gear up accordingly to mitigate the concerns, yet ensuring that the operational effectiveness of the Armed Forces is not compromised. The issue was extensively covered by the media, and the Armed Forces responded positively with Army Chief indicating that the roadmap for granting permanent commission to women officers is being put in place. The implementation, however, needs some serious analysis of some key issues to.

Decoding Alleged Gender Bias in Indian Armed Forces

A glance at the open-source coverage of SC decisions, seemed to suggest that Indian Military had the patriarchal mindset and SC has bettered the system with this landmark judgement. The background needs to be put into perspective. The women were first inducted as Military Nursing Officers in 1927, as Medical Officers from 1943 in British Indian Army as per organisational needs to look after troops, families and public during deployments, which included female population. Post-independence, the Induction of women officers into the Indian Army through Women Special Entry Scheme (WSES) started in 1992, after the approval of the Cabinet Committee on Parliamentary Affairs.

In February 2019, the government granted a permanent commission to women officers in eight streams of the Army, in addition to the JAG and AEC, to which it was granted earlier in 2008. All these decisions were also pathbreaking, need-driven, societal changes taken voluntarily by Indian Military and not after the intervention of Courts; hence it may not be right to perceive that Indian Military carried patriarchal mindset and resisted such changes. It is a fact that there are different conditions of service for women officers and their men counterpart in most cases. These conditions of service keep getting modified to address concerns of women officers, starting from five years of service, changed to extendable by five years (5+5 years), followed by 5+5+4 and later made to 10+4 years.

The fact is that women officers are proud and essential members of the Indian military and their entry was need-based and not court driven.

The differences in conditions of service for women officers and their men counterparts can be perceived in favour, as well as, against them. No one can deny that women officers have concessions in physical standards during recruitment, in battle physical efficiency tests and are generally given softer appointments with due considerations to hygiene, sensitivities and privacy issues while accommodating them.

For selection they compete with female counterparts; hence selections of a specified number of women officers is assured, as they do not compete with men counterparts. The disadvantages of difference in service conditions were unequal growth opportunity to women officers, need for permanent commission and inadequate incentive, which have been the main reasons for the redressal given the Supreme Court. The cases wherein male officers tenures in difficult field stations have increased, in adjusting women officers for spouse postings, child care leave. This results in reduced leaves for male officers to be with family in peace locations, to attend to their family needs. Although male officers have not gone to courts against the resultant extra hardship caused in an attempt to help out women officers by the organisation.

This gender bias against men officers also needs to be set right. Gender Equality is the societal need of the hour and applies to both female and male officers and should be ensured in the spirit of the judgement.

Operational Efficiency and Command Assignments

To implement the latest rulings of the SC on the grant of permanent commission to all women officers, their terms of engagement will have to be revised. As per media report,s the Indian Military is already working out models for it and I am sure that the system will settle down in due course, with some adjustments. The selection for command assignments has to merit-based irrespective of gender, which must not be compromised to ensure operational efficiency of the Indian Armed Forces. Translating the same in the spirit of achieving gender equality and SC judgement, the same standards have to be applied across the board, without any gender bias.It entails same hardships be suffered by all officers and the same selection process followed for successive promotions, irrespective of the gender.

To implement the same, the selection for the command should be done through their confidential reports and closed promotion board, common for both genders, and the names and gender of the profile should be hidden from selection board.

The best officers should get the command irrespective of gender, as the troops respect competent leaders, who rough out inconvenient times with them. These are some basics of soldiering, which must not be violated to ensure operational efficiency. It means that the concessions given to women officers in recruitment and softer tenures must be withdrawn, and they must go through the field and rough appointments with troops, to be at par with male counterparts and be accepted as Leaders and not Appointed Officers.

Women Officersin Combat Arms

The fact that SC gave a decision, in March 2020, to induct women officers in all types of warships in Indian Navy, as a natural process of societal evolution, the possible induction of women into combat arms is going to be the next challenge, which Indian Military will be confronted with. The leadership in combat arms at each level, from detachment to highest formation, is laid on a bedrock principle of Leading from the front which must not be compromised.

It implies that all officers and soldiers must go through same selection, toughness schedule, promotion exams, command criteria assignments and appointments with no concessions. SC has also endorsed suitability of the candidate as one of the criteria for such assignments in its ruling on March 17, 2020. Most foreign armies having women officers already have gender neutrality in physical standards or are working towards it. The issues like physiology, minimal facilities for habitat, hygiene in combat ships, bunkers and long-range patrols, privacy needs, motherhood and childcare concerns are well known to women officers, as well as, courts and public.

The women officers who volunteer for combat arms must be determined to overcome these issues. The only aspect which needs to be ensured is that the standards should not be lowered to adjust women officers, otherwise it will amount to compromising operational effectiveness of military for appeasement of few.

The principle for selections in career progression should be the same as explained earlier for command assignments. It, therefore, implies that if every male infantry officer has to go through commando course, every women officer opting for infantry must go through the same. If every other combat arms officer has to go through Commando/Counterinsurgency/Mountain warfare course and serve in Rashtriya Rifle or Assam Rifle for at least one tenure, the same yardstick must apply to women officers.

(Disclaimer: The opinions expressed above are the personal views of the author and do not reflect the views of ZMCL)

Link:
Equal roles for women in Indian Armed Forces: The road ahead - WION

Rutgers Researcher Partners with NYU in Creating Sleep Apnea Machine Alternative to Ventilators and a Virus-Trapping Hood – Newswise

Newswise A Rutgers researcher is testing modified sleep apnea machines intended to help relieve the shortage of mechanical ventilators for COVID-19 patients.

After testing for safety and efficacy, the design will be available free to medical professionals and can be created quickly using readily available components. It was created by a team led by Vikram Kapila, a professor at the New York University Tandon School of Engineering.

Patients using the modified breathing supports called the NYU Tandon AirMOD wear a non-vented mask with filters that trap the virus when they exhale and keep it from entering the environment. The machines also can be used as breathing support for critical care patients being eased off ventilators, thereby freeing those ventilators for other patients. Unlike other methods being used to convert these CPAP and BiPAP sleep apnea machines for COVID-19 use, these design modifications assemble in minutes and use FDA-approved off-the-shelf components in stock at most hospitals.

Rutgers is also testing a prototype for a second system called the NYU Tandon AirVENT. It is a portable, personal, negative pressure hood that sucks virus particles exhaled by the wearer into a filter and traps them. The hood was designed to allow health care workers easy access to the patient. It can be placed over possible COVID-19 patients in waiting rooms and be used in ICUs, while physicians intubate patients or during patient transfers.

Jorge Serrador, associate professor of pharmacology, physiology and neuroscience at Rutgers New Jersey Medical School, is testing both systems for safety and efficacy. A normal CPAP or BiPAP machine would spread the virus widely because not only is the mask vented, but pressurized air from the system would amplify the dispersion of the virus. The AirMOD design cuts off that avenue of exhaust and uses a system that filters out the virus before it enters the environment, he said.

To test the designs, Serrador measured how much carbon dioxide, which is expelled through breathing, is present outside the devices while they are being used. When we turn on the fan inside the hood, we see the level of carbon dioxide outside the hood decrease to the level seen in normal room air, which indicates that expired air and thus the virus is not escaping, he said. Negative pressure rooms are already used safely for infectious disease patients. We have just created a personal negative pressure area around the patients head. (See test results here.)

The AirMOD design is less expensive than ventilators and has other benefits to health care workers, such as being portable and requiring minimal set-up. There are also benefits to patients, Serrador said. It gives people the assistance they need in their natural breathing to maintain their oxygen levels while allowing their bodies to deal with the virus. Since they are not intubated, they do not need to be sedated and can talk, clear their throats and cough, which helps prevent pneumonia.

The AirMOD modifications were also reviewed by pulmonologists and physicians at NYU Langone and other centers. The designs can be downloaded here.

The rest is here:
Rutgers Researcher Partners with NYU in Creating Sleep Apnea Machine Alternative to Ventilators and a Virus-Trapping Hood - Newswise

Genetic Testing: Are Over-the-Counter Options Reliable? – Curetoday.com

An expert raises her concerns about direct-to-consumer testing and shares ways people can protect themselves.

In an interview with CURE, Lisa Schlager, vice president of public policy for Facing Our Risk of Cancer Empowered (FORCE) and a BRCA1 mutation carrier, discussed OTC genetic tests versus those provided by health care professionals and what consumers should keep in mind as they make health decisions.

CURE: What are the major differences between OTC genetic tests and those ordered by a physician or genetic counselor?

Schlager: Its like night and day. As an example, 23andMe has a component where you can opt to test for the BRCA mutations, although it looks for only three of the potentially thousands of BRCA mutations. The BRCA1 and BRCA2 gene mutations are associated with increased risk of breast, ovarian, prostate and pancreatic cancer, and some people are interested to know if they may have one of these mutations.

But when youre testing for only three of the potentially 5,000 mutations, and those three mutations are most commonly found in the Ashkenazi Jewish population, youre going to miss a lot of information. The fact that the Ashkenazi Jewish population is about 2% of the population in the United States means that 98% of the population in this country is unlikely to have those specific mutations.

If you were to go to a genetic counselor or a health care specialist with expertise in genetics, they would talk to you about your family history, determine which testing is most appropriate and probably give you a test that is much more expansive.

We must understand also that BRCA mutations are not the only mutations that cause an increased risk of cancer. We now have dozens of mutations with names like PALB2, CHEK2, ATM and Lynch syndrome. These are all mutations that cause increased cancer risk, and if you test for only the three BRCA mutations, youre really not getting good information about your potential risk.

How can consumers determine which OTC tests are reputable?

There have been a lot of reports in the media of people selling tests to unwitting consumers who dont realize who they are dealing with, who dont realize that theyre being duped out of their insurance or Medicare information. I think the important thing is that if you go to a qualified health care professional, they are more likely to steer you to a reputable genetic test. If youre going to do a test over the counter, look at it for what it is. Its kind of a fun thing, and it may provide you with some interesting information, but the best place to learn about health risks and health conditions is through a qualified health care professional or genetics counselor. Ultimately, if you do test positive for one of these health risks ... you need to confirm it with a health care provider anyway. The other thing to be aware of is that if something seems suspicious, go with your gut.

Should consumers be more aware of certain characteristics of these fraudulent tests?

Absolutely. (Be wary of) those that are making promises about coverage and that everyone is able to get it covered now, 100% free or no cost to you, or if they are aggressively marketing. We have seen people marketing these tests at health fairs and senior centers. Thats not a reputable way to do this. Thats not how health care is supposed to be done.

Some of these tests, such as 23andMe, have been approved by the Food and Drug Administration (FDA). What does this mean?

FDA approval means that the FDA has vetted it and determined that the test is in fact accurate for what it claims to do. The reality is that the vast majority of genetic tests are not FDA approved, they are CLIA (Clinical Laboratory Improvement Amendments) approved, which is a designation under the Centers for Medicare & Medicaid Services.

So, it comes down to knowing who is providing the test to you and making sure that the company, the test provider, the laboratory, is a reputable lab.

What is the biggest takeaway for consumers who are concerned about their risk?

Talk to a doctor that you have a relationship with and share your concerns. Most doctors will either have a mechanism for assessing risk in office or will refer you.

Ultimately, there is coverage for genetic testing for people who have a family history or personal cancer history. People dont need to turn to these less reliable tests to get the testing.

Originally posted here:
Genetic Testing: Are Over-the-Counter Options Reliable? - Curetoday.com

The Better Half by Sharon Moalem review on the genetic superiority of women – The Guardian

Lets hear it for the female of the species and (more guardedly) for her second X-chromosome! Female superiority in colour vision, immune response, longevity, even basic survival from birth to death are illustrated in Sharon Moalems The Better Half. After decades, if not centuries, of bad press for women and their vulnerable biology, this book argues that in fact almost everything that is biologically difficult to do in life is done better by females.

Moalem, a Canadian-born physician, is a research geneticist who has identified two new rare genetic conditions. He has worked across the world in paediatric medicine, including clinics for HIV-infected infants and is also a biotechnology entrepreneur and bestselling author. The Better Half is his latest foray into the field of popular science, and presents a general argument for the superiority of womens biology to mens.

In most circumstances, a human female has two X-chromosomes, one from her father and one from her mother; a male has just one, inherited from his mother, which is paired with a Y-chromosome, inherited from his father. Moalem believes that the X-chromosome has always received a poor press, and that it is time this negative view is counteracted. He draws on swathes of medical and historical data to show that, in many instances, the superiority of womens biology is explicitly linked to their possession of the second X-chromosome. The greater complexity of womens biology, he claims, is the secret of their success it is more difficult to make a female but, once made, she trumps the male in her lifelong survival skills, for instance in her hyperefficient immune system shrugging off infection and maximising the benefits of vaccination which means that females can avoid the consequences of a wide range of life threatening events ranging from starvation and cancer to, Moalem has cautiously concluded, Covid-19.

In mainstream genetics it was long held that, despite having two X-chromosomes, female cells only made use of one: the second randomly switched off or deactivated early on in embryonic development, a process rather summarily described as an instance of genetic redundancy. There was some evidence that the deactivation reduced female chances of succumbing to X-linked problems, due to the availability of an undamaged back-up. It was acknowledged, for example (though rather grudgingly), that women generally escaped being colour blind. Moalem notes that when he was studying genetics there was much emphasis on the tiny Y-chromosome as what makes a man. He observes wryly that maybe this positivity was related to the fact that most of the people who were speaking breathlessly about the Y had one as well.

Now a new spin on the X-inactivation story is emerging in genetics. Via a process called escape from X-inactivation, it turns out that the silenced X-chromosome is not so silent after all there are escapees which may continue to offer back-up services, for instance providing extra cellular recovery options in the face of traumatic injury. It is to the benefits offered by this flexible availability within different cells that Moalem attributes the secrets of womens biological superiority.

Statistics going back as far as 1662 show women living longer than men, and todays figures show that 95% of people who have reached the age of 110 and over are female. In sport, womens success in races such as ultra-marathons offer a different perspective on what it means to be physically superior. In the spirit of Angela Sainis book Inferior, Moalem notes that this superiority has largely been ignored by medical science. And he discusses the medical trial data whose absence is observed by Caroline Criado-Perez in Invisible Women, her exploration of how the world is designed for men. Medicine needs to stop ignoring the secrets of womens biological successes, Moalem argues, and find ways of harnessing them to improve the survival chances of the whole of the human race.

Imagine you live in a world where most individuals can see 1m colours. But in one group of these people (lets call them males), about 8% cannot tell the difference between colours such as red and green, and a smaller number are totally colour blind. In a second group in this population (lets call them females), almost all can see the standard 1m colours, but some (perhaps as many as 15%) can see 100m colours. Would you excitedly rave about the amazing talent of this latter group? Or would you just describe them as not usually colour blind? This same group has an immune system that has a profound talent to fight off many forms of infection and reap major benefits from vaccinations with the down side that sometimes such hyperefficiency can lead to autoimmune disorders such as multiple sclerosis. Would you celebrate the former or emphasise the latter? For years, it is the drawbacks that have been underlined.

Research geneticists rarely get out in the field to notice the much greater survival rates of girls in paediatric ICUs

The Better Half is an eye-opening book. In explaining why the advantages that accompany females greater genetic options have to date been largely ignored, Moalem points to paradigm blindness, and to the fact that research geneticists rarely get out in the field to notice, for example, the much greater survival rates of girls in paediatric ICUs (rates which, he discovers, have been clearly obvious to the nurses doing the frontline caring).

I take issue with one part of his chapter on The Male Brain, for the moment setting aside the unproven assumption that the brains of men are different from the brains of women. Moalem chooses to consider autism, and it appears as a given in his book that autism is more common in boys than girls (itself an assumption that is increasingly being challenged). Yet at the more impaired end of the autism spectrum, it is possible that there are as many girls as boys, and his suggestion that females have a different kind of autism doesnt quite prove his wider argument. The X-linked disorders such as fragile-X or Rett syndrome receive only a passing mention not surprisingly perhaps as they run counter to his argument about the superiority of the X-chromosome.

What about hormones? Moalem has perhaps missed a good opportunity to counter oestrogens frequently negative press, and to laud its potentially neuroprotective effects. The greater susceptibility of women to Alzheimers disease is put down by Moalem to a form of anti-inflammatory process linked to an overefficient immune system; their lesser susceptibility to Parkinsons disease (surely a possible inclusion in the list of female genetic successes) is unexplained.

One section of the book focuses on why womens health is not mens health, and considers the failures of drug companies to test their products on females as well as males. For sure this has had detrimental consequences on, for example, the accuracy of dosage rates. But in at least one of the examples he gives, that of Ambien, body mass and blood volume are key factors in calculating dosage rates: because people vary enormously in size and shape, simply dividing test participants into males and females still risks inaccuracy. He is talking about averages, its true, but even so Moalem seems firmly wedded to the notion that genetic females and genetic males can be neatly categorised into two distinct types, and that the understanding of genetic sex will provide all the answers we need.

The impression given in The Better Half is that there is a lifelongfree-ranging choice between X-chromosomes available to the female, her cells dancing back and forth between the best options that will help her to heal quicker after a car crash or to overcome the bacterial infection that might lead to an ulcer. There are brief and tantalising hints about the escapees from X-inactivation in several chapters of Moalems book, but it is a shame that we are never given a full, head-on account.

Yet this book is full of wonderful titbits of information from the existence of a female prostate gland to the number of honey bee flying miles it takes to make 1lb of honey. The celebration of the genetic diversity offered by the females second X-chromosome is wholehearted and the examples Moalem gives are highly effective. He has written a powerful antidote to the myth of the weaker sex.

The Better Half: On the Genetic Superiority of Women by Sharon Moalem is published by Allen Lane (RRP 20).

See the rest here:
The Better Half by Sharon Moalem review on the genetic superiority of women - The Guardian

New Tool Helps Gather Useful Genetic Information Obtained from Blood, Skin Tissues – Global Health News Wire

Researchers at CHOP and University of Pennsylvania developed an online tool to refine results from RNA sequencing obtained from clinically accessible tissues

DNA sequencing is becoming a more commonplace method for detecting diseases and improving precision medicine. Because DNA sequencing does not detect all possible disease-causing mutations, RNA sequencing is often used to address this important gap. However, RNA sequencing is typically performed on clinically-accessible tissues from blood and skin and likely does not represent a complete view of the rest of the body.

Hoping to refine the usefulness of RNA sequencing, a team of researchers from Childrens Hospital of Philadelphia (CHOP) and the Perelman School of Medicine at the University of Pennsylvania reviewed a database of RNA sequencing results in non-clinically-accessible tissues from organs like the brain and heart. This helped them identify differences between tissues that were well expressed to help identify when clinically-accessible tissues like blood and skin samples are most useful and when they are not. To aid future sequencing and aid diagnosis, the study team also developed an online resource outlining how these differences affect specific tissues and genes of interest. The findings were published in the journal Genetics in Medicine.

Researchers continue to improve the ability of sequencing tests to detect genetic mutations that drive disease. Exome sequencing captures about 31% of inherited genetic disorders, and genome sequencing improves this rate somewhere between 10% and 15%, meaning that the majority of patients who receive this screening will not receive a proper molecular diagnosis. One of the primary difficulties is the number of non-coding variants these tests capture. These variants are capable of causing disease, but they are difficult to predict and therefore often ignored by existing diagnostic techniques.

One way these variants can cause problems is their ability to alter RNA splicing, or the process by which non-coding parts of genes are removed so that only the coding portions are available to create necessary proteins. Therefore, variants that affect RNA splicing can alter the function of essential proteins, which can lead to disease. RNA sequencing can help detect these variants and add to the knowledge gleaned from exome and genome sequencing. However, RNA sequencing is complicated because the gene must be expressed in the tissue of interest, and often those tissues are not accessible.

We know that we are unable to test tissues in the brain, heart and certain other organs for diagnostic purposes, but we also know that using RNA sequencing on these tissues could reveal important genetic information we might not otherwise be able to capture, said Elizabeth Bhoj, MD PhD, an attending physician with the Division of Human Genetics at CHOP, an assistant professor of pediatrics at the Perelman School of Medicine, and senior co-author of the study. By studying both clinically- and non-clinically-available tissues, we hoped this study would reveal the true extent of what we may be missing with current RNA sequencing methods.

The study team quantified RNA splicing in 801 RNA-sequenced samples from 56 different adult and fetal tissues. Genes and splicing events were identified by the team in each non-clinically-available tissue, which then allowed the researchers to determine when RNA sequencing in each clinically-available tissue actually inadequately represents them. The team then developed its own online resource, MAJIQ-CAT, so that others could explore their analysis for specific genes and tissues.

The researchers found that 40.2% of non-clinically-available tissues have RNA splicing that is inadequately represented in at least one clinically-available tissue, and 6.3% of genes have splicing inadequately represented by all clinically-available tissues. While a majority (52.1%) of these genes have low expression in clinically-available tissues, the study team showed that 5.8% are inadequately represented despite being well-expressed, thereby representing a significant portion of genes of interest not being properly captured by traditional RNA sequencing methods.

By using MAJIQ-CAT, researchers can determine which accessible tissues, if any, best represent RNA splicing in genes and tissues of interest, Bhoj said. While this does not address the entire gap left by current exome and genome sequencing methods, we believe we can capture more genes and determine how they affect human health.

The research team drew from their diverse scientific backgrounds for this study to improve clinical diagnosis. Bhoj and her lab provided expertise in genetics and clinical diagnostics with the computational expertise of the lab of Yoseph Barash, PhD, an associate professor in the Department of Genetics at Penn. The work was led by Joseph Aicher, an MD/PhD student in the Genomics and Computational Biology program at Penn who was co-mentored by Bhoj and Barash.

Follow this link:
New Tool Helps Gather Useful Genetic Information Obtained from Blood, Skin Tissues - Global Health News Wire

Here’s how scientists are tracking the genetic evolution of COVID-19 – TheStreet

Niema Moshiri, University of California San Diego

When you hear the term evolutionary tree, you may think of Charles Darwin and the study of the relationships between different species over the span of millions of years.

While the concept of an evolutionary tree originated in Darwins On the Origin of Species, one can apply this concept to anything that evolves, including viruses. Scientists can study the evolution of SARS-CoV-2 to learn more about how the genes of the virus function. It is also useful to make inferences about the spread of the virus around the world, and what type of vaccine may be most effective.

I am a bioinformatician who studies the relationships between epidemics and viral evolution, and I am among the many researchers now studying the evolution of SARS-CoV-2 because it can help researchers and public health officials track the spread of the virus over time. What we are finding is that the SARS-CoV-2 virus appears to be mutating more slowly than the seasonal flu which may allow scientists to develop a vaccine.

Viruses evolve by mutating. That is, there are changes in their genetic code over time. The way it happens is a little like that game of telephone. Amy is the first player, and her word is CAT. She whispers her word to Ben, who accidentally hears MAT. Ben whispers his word to Carlos, who hears MAD. As the game of telephone goes on, the word will transform further and further away from its original form.

We can think of a biological genetic material as a sequence of letters, and over time, sequences mutate: The letters of the sequence can change. Scientists have developed various models of sequence evolution to help them study how mutations occur over time.

Much like our game of telephone, the genome sequence of the SARS-CoV-2 virus changes over time: Mutations occur randomly, and any changes that occur in a given virus will be inherited by all copies of the next generation. Then, much as we could try to decode how CAT became MAD, scientists can use models on genetic evolution to try to determine the most likely evolutionary history of the virus.

DNA sequencing is the process of experimentally finding the sequence of nucleotides (A, C, G and T) the chemical building blocks of genes of a piece of DNA. DNA sequencing is largely used to study human diseases and genetics, but in recent years, sequencing has become a routine part of viral point of care, and as sequencing becomes cheaper and cheaper, viral sequencing will become even more frequent as time progresses.

RNA is a molecule similar to DNA, and it is essentially a temporary copy of a short segment of DNA. Specifically, in the central dogma of biology, DNA is transcribed into RNA. SARS-CoV-2 is an RNA virus, meaning our DNA sequencing technologies cannot directly decode its sequence. However, scientists can first reverse transcribe the RNA of the virus into complementary DNA (or cDNA), which can then be sequenced.

Given a collection of viral genome sequences, we can use our models of sequence evolution to predict the viruss history, and we can use this to answer questions like, How fast do mutations occur? or Where in the genome do mutations occur? Knowing which genes are mutating frequently can be useful in drug design.

Tracking how viruses have changed in a location can also answer questions like, How many separate outbreaks exist in my community? This type of information can help public health officials contain the spread of the virus.

For COVID-19, there has been a global initiative to share viral genomes with all scientists. Given a collection of sequences with sample dates, scientists can infer the evolutionary history of the samples in real-time and use the information to infer the history of transmissions.

One such initiative is Nextstrain, an open-source project that provides users real-time reports of the spread of seasonal influenza, Ebola and many other infectious diseases. Most recently, it has been spearheading the evolutionary tracking of COVID-19 by providing a real-time analysis as well as a situation report meant to be readable by the general public. Further, the project enables the global population to benefit from its efforts by translating the situation report to many other languages.

As the amount of available information grows, scientists need faster tools to be able to crunch the numbers. My lab at UC San Diego, in collaboration with the System Energy Efficiency (SEE) Lab led by Professor Tajana imuni? Rosing, is working to create new algorithms, software tools and computer hardware to make the real-time analysis of the COVID-19 epidemic more feasible.

Based on current data, it seems as though SARS-CoV-2 mutates much more slowly than the seasonal flu. Specifically, SARS-CoV-2 seems to have a mutation rate of less than 25 mutations per year, whereas the seasonal flu has a mutation rate of almost 50 mutations per year.

Given that the SARS-CoV-2 genome is almost twice as large as the seasonal flu genome, it seems as though the seasonal flu mutates roughly four times as fast as SARS-CoV-2. The fact that the seasonal flu mutates so quickly is precisely why it is able to evade our vaccines, so the significantly slower mutation rate of SARS-CoV-2 gives us hope for the potential development of effective long-lasting vaccines against the virus.

[Get facts about coronavirus and the latest research. Sign up for The Conversations newsletter.]

Niema Moshiri, Assistant Teaching Professor of Computer Science & Engineering, University of California San Diego

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Read more:
Here's how scientists are tracking the genetic evolution of COVID-19 - TheStreet